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A b s t r a c t
Introduction: We investigated the effects of ghrelin on protein expression 
of the liver antioxidant enzymes superoxide dismutases (SODs), catalase 
(CAT), glutathione peroxidase (GPx), and glutathione reductase (GR), nuclear 
factor κB (NFκB) and inducible nitric oxide synthase (iNOS). Furthermore, 
we aimed to investigate whether extracellular regulated protein kinase 
(ERK1/2) and protein kinase B (Akt) are involved in ghrelin-regulated liver 
antioxidant enzymes and iNOS protein expression.
Material and methods: Male Wistar rats were treated with ghrelin (0.3 nmol/ 
5 µl) injected into the lateral cerebral ventricle every 24 h for 5 days, and 
2 h after the last treatment the animals were sacrificed and the liver excised. 
The Western blot method was used to determine expression of antioxi-
dant enzymes, iNOS, phosphorylation of Akt, ERK1/2 and nuclear factor κB 
(NFκB) subunits 50 and 65.
Results: There was significantly higher protein expression of CuZnSOD 
(p < 0.001), MnSOD (p < 0.001), CAT (p < 0.001), GPx, (p < 0.001), and GR 
(p < 0.01) in the liver isolated from ghrelin-treated animals compared with 
control animals. In contrast, ghrelin significantly (p < 0.01) reduced protein 
expression of iNOS. In addition, phosphorylation of NFκB subunits p65 and 
p50 was significantly (p < 0.001 for p65; p < 0.05 for p50) reduced by ghrelin 
when compared with controls. Phosphorylation of ERK1/2 and of Akt was 
significantly higher in ghrelin-treated than in control animals (p < 0.05 for 
ERK1/2; p < 0.01 for Akt).
Conclusions: The results show that activation of Akt and ERK1/2 is involved 
in ghrelin-mediated regulation of protein expression of antioxidant enzymes 
and iNOS in the rat liver.
Key words: Akt, ERK1/2, superoxide dismutase, catalase, oxidative stress, 
nuclear factor κB.
Introduction
Ghrelin, a 28 amino acid peptide, is the main endogenous ligand for 
the growth hormone (GH) secretagogue receptor (GHSR) [1, 2], and is 
secreted primarily from the stomach, but its transcripts have also been 
found in the liver, suggesting its extra-endocrine as well as endocrine 
action [1–3]. The relationship between oxidative stress (OxS) and the 
expression or function of ghrelin has been reported by several research-
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ers [4–6]. In addition, ghrelin administration is ex-
pected to reduce OxS and thereafter prevent the 
onset of different diseases [5, 7]. Moreover, ghrelin 
has an anti-inflammatory action on the oxidative 
injury of diverse organs, such as the heart, liver 
and pancreas [5, 8–12]. 
Oxidative stress reflects an excessive bioavail-
ability of reactive oxygen species (ROS), which is 
the net result of an existing imbalance between 
production and destruction of ROS, with the latter 
being affected by antioxidant defenses [13]. The 
removal of ROS and free radicals [14] is achieved 
through enzymatic and non-enzymatic reactions. 
Antioxidant enzymes such as superoxide dismu-
tase (SOD), catalase (CAT), glutathione peroxidase 
(GPx) and glutathione reductase (GR) represent 
protective response against oxidative tissue dam-
age [1, 15]. 
Inducible nitric oxide synthase (iNOS; NOS2) is 
a protein that produces high amounts of nitric ox-
ide (NO), and NO is highly reactive with other free 
radicals. Nitric oxide reacts with superoxide (O
2
–) 
producing peroxynitrite, which in turn leads to 
protein nitration, DNA damage, and poly (ADP-ri-
bose) polymerase activation [16, 17]. Therefore, 
the predominant role of iNOS is thought to relate 
to OxS-mediated host defense against tumor cells 
and microorganisms [16, 18]. 
Upregulation of iNOS gene transcription re-
quires the transcriptional factor nuclear fac-
tor-κB (NFκB) in human and rat hepatocytes 
[19]. In inflamed liver, liver cells are situated in 
an environment where NO is generated from 
surrounding cells and from liver cells themselves 
[19, 20]. It has been shown that redox-sensi-
tive transcriptional factor NFκB is an important 
stress sensor playing a crucial role in determin-
ing cellular fate during OxS [21, 22]. Nuclear fac-
tor κB is known to be activated by ROS and its 
activation leads to the transcriptional activation 
of numerous genes including antioxidant en-
zymes and iNOS [22–27].
The effects of ghrelin are mediated via a com-
plex set of intracellular signaling pathways, includ-
ing two kinases, extracellular regulated protein ki-
nase (ERK1/2) and protein kinase B (Akt) [20, 28]. 
With the studies presented in this paper, the 
overall hypothesis that ghrelin is involved in anti-
oxidative enzymes and iNOS protein expression in 
the liver is pursued. Furthermore, we hypothesized 
that ERK1/2 and Akt are involved in ghrelin-reg-
ulated antioxidant enzymes and iNOS in the rat 
liver. Given the complexity of the ghrelin system it-
self, and the limited amount of data related to the 
effects of ghrelin on regulation of liver antioxidant 
enzymes and iNOS in vivo, we investigated wheth-
er 5 days treatment with ghrelin caused chang-
es in the liver protein expression of antioxidant 
enzymes and iNOS, and whether these changes 
in their level could be related to changes of the 
transcriptional regulator NFκB as well as changes 
of activation of ERK1/2 and Akt.
Material and methods 
Materials 
Pentobarbital anesthetic was obtained from 
United Pharmaceutical Works, Prague, Czech 
Republic, and ether was obtained from “Lek”, 
Ljubljana, Slovenia. Ghrelin was obtained from 
Global Peptide Services, LLC Ft. Collins, CO, USA. 
A protease inhibitor cocktail (Complete Mini) was 
obtained from Roche, Mannheim, Germany. Re-
agents for the bicinchoninic acid (BCA) assay were 
purchased from Pierce (Rockford, IL, USA). Anti-ac-
tin monoclonal antibody was obtained from Sig-
ma Aldrich Corporation (St. Louis, MO, USA) and 
from Abcam (Cambridge, U.K.). Anti-phospho-Akt 
Ser473, the anti-total Akt, the anti-phospho-ERK1/2, 
and the anti-total ERK1/2 antibodies were pur-
chased from Cell Signaling (Beverly, MA, USA), 
while the anti-iNOS, the anti-NF-κB p65 and p50 
antibodies and the secondary anti-rabbit antibod-
ies conjugated to alkaline phosphatase (ALP) or 
to horseradish peroxidase (HRP) were purchased 
from Santa Cruz Biotechnology, Inc. (Santa Cruz, 
CA, USA) and from Amersham (Piscataway, NJ). 
Anti- MnSOD, anti-CuZnSOD, anti-GPx, and anti-GR 
antibodies were purchased from Stressgen (Now: 
Enzo Life Sciences, NY, USA) and an anti-catalase 
antibody from Calbiochem (CA, USA).
An enhanced chemiluminescence (ECL) kit and 
HRP-linked rabbit IgG were obtained from Pierce 
(Rockford, IL, USA) or from Amersham Pharmacia 
Biotech (Buckinghamshire, UK). X-ray films were 
purchased from Agfa (Belgium). A commercial ra-
dioimmunoassay (RIA) kit was obtained from INEP, 
Zemun, Serbia, and the GLUC-PAP commercial test 
was obtained from Randox (Crumlin, UK).
Animals 
Adult male Wistar rats (200–250 g), bred at 
the Institute of Biomedical Research “Galenika” 
in Belgrade, were used. The rats were kept in in-
dividual metabolic cages under a 12 : 12-h light–
dark cycle, at 22 ±2°C, and were fed with a bal-
anced diet for laboratory rats composed of 20% 
protein, 8% cellulose, 13% moisture, 1% calcium, 
0.90% lysine, 0.75% methionine + cysteine, 0.5% 
phosphorus, 0.15–0.25% sodium, vitamin mixture 
(A  10,000 IU/kg, D 3 1,600 IU/kg, E 25 mg/kg, 
B 12 0.02 mg/kg), a mixture of minerals (in milli-
grams per kg: zinc 100, iron 100, manganese 30, 
copper 20, iodine 0.5, selenium 0.1), antioxidants 
100 mg/kg, and digestible/metabolizable energy 
11 MJ/kg (prepared by “D. D. Veterinarski zavod 
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Subotica”, Subotica, Serbia). Food and water were 
available to rats ad libitum. Body weight was mea-
sured daily. 
Experimental protocols were approved by the 
official Vinca Institute’s Ethical Committee for Ex-
perimental Animals and conformed to the recom-
mendations given in “Guide for the Care and Use 
of Laboratory Animals” (1996 National Academy 
Press, Washington, D.C., USA). 
Surgical procedures
Surgical procedures were performed under 
pentobarbital (45–50 mg/kg; intraperitoneally) 
and ether anesthesia. The rats were implanted 
with a  headset and later used for intracerebro-
ventricular (ICV) injections. A  minimum recovery 
time of 5 days was permitted before the onset 
of experiments. The headset consisted of a silas-
tic-sealed 20G cannula [20, 29–31], implanted into 
a  lateral cerebral ventricle 1 mm posterior and 
1.5 mm lateral to the bregma and 3 mm below 
the cortical surface. A small stainless steel anchor 
screw was placed at a  remote site on the skull. 
The cannula and screw were cemented to the skull 
with dental acrylic. 
Experimental treatment 
After recovery, rats were divided into two 
groups (each consisting of six animals). The first 
group of rats, labeled as ghrelin, was treated ICV 
with 1 µg of ghrelin dissolved in 5 µl of phosphate 
buffered saline (PBS) every 24 h for 5 consecu-
tive days [20, 30, 31]. The second group of con-
trol rats, labeled as CONTROL, was injected with 
5 µl of PBS. All ICV treatments were administered 
between 10:00 and 11:00 a.m., and animals were 
euthanized by decapitation under deep ether 
anesthesia 2 h after the last ICV injection. Livers 
were excised, weighed, and used for experiments. 
Blood was collected from each rat immediately 
after decapitation. Serum samples were stored at 
–20°C for measuring insulin, glucose and free fat-
ty acid (FFA).
Liver lysate preparation
After decapitation, rat livers were homogenized 
on ice with an Ultra-turrax homogenizer in buf-
fer (pH 7.4) containing (in mM): 150 NaCl, 50 Tris, 
2 EDTA, 10% glycerol, 1% Triton X-100, protease 
inhibitor cocktail with additional 2 mM PMSF, and 
2 mM sodium orthovanadate. Homogenates were 
centrifuged at 600×g for 20 min at 4°C, and ob-
tained supernatants were ultra-centrifuged for 
60 min at 100,000×g [32], and used as the cyto-
plasmic fraction. Protein concentration was de-
termined by the BCA method using bovine serum 
albumin as standard.
Determination of serum insulin, glucose 
and free fatty acid concentrations 
Serum insulin levels were determined by the 
RIA method, using rat insulin standards, with as-
say sensitivity of 0.6 mIU/l and an intra-assay co-
efficient of variation of 5.24% and expressed as 
mIU/l of serum. The glucose levels were measured 
using a  GLUC-PAP kit according to the manufac-
turer’s manual and expressed as mmol/l. For mea-
surement of serum insulin, glucose and free fatty 
acid (FFA) levels animals were fasted overnight be-
fore collection of blood samples in order to avoid 
changes of insulin, glucose and FFA level induced 
by food intake. The serum FFA levels were deter-
mined using a  modified version of Duncombe’s 
colorimetric method [33] and expressed as mmol/l.
Also, fasting serum concentrations of both glu-
cose and insulin were used to calculate the indices 
of insulin resistance [homeostasis model assess-
ment (HOMA)-IR] and insulin secretion (HOMA-β) 
with the following formulae [34]: HOMA-IR = fast-
ing insulin (µU/ml) × fasting glucose (mM)/22.5 
and HOMA-β = 20 × fasting insulin (µU/ml)/(fast-
ing glucose (mM) – 3.5). 
SDS-PAGE and Western blotting 
Equal amounts of protein (50 or 60 µg/lane) 
were separated by 10% SDS polyacrylamide gels 
[35–37] and transferred to polyvinylidene difluo-
ride membranes as previously described [38, 39]. 
The membranes were blocked with either 5% 
nonfat dry milk or 5% bovine albumin and probed 
with antibodies against MnSOD (in a  dilution of 
1 : 4000), CuZnSOD (in a dilution of 1 : 10000), GPx 
(in a dilution of 1 : 1000), GR (in a dilution of 1 : 3000), 
iNOS (in a dilution of 1 : 2000), NFκB subunits p50 
(in a dilution of 1 : 1000) and p65 (in a dilution of 
1 : 500). After washing, membranes were incubat-
ed with the appropriate secondary ALP-conjugat-
ed anti-rabbit antibody (in a dilution of 1 : 2000) 
and used for subsequent detection with 5-bromo-
4-chloro-3-indoyl phosphate and nitroblue tetra-
zolium, or with the appropriate secondary HRP- 
conjugated anti-rabbit antibody (in a  dilution of 
1 : 2000) or with ECL Rabbit IgG, HRP-linked whole 
antibody (in a  dilution of 1 : 5000) or with ECL 
Mouse IgG, HRP-linked whole antibody (in a dilu-
tion of 1 : 2000) and used for subsequent detec-
tion by using an ECL kit. After analysis of pAkt 
(in a dilution of 1 : 1000) and pERK1/2 (in a dilu-
tion of 1 : 1000), membranes were stripped and 
reblotted with antibody detecting total Akt (in a di-
lution of 1 : 1000) or total ERK1/2 (in a dilution of 
1 : 1000). In order to ensure equal protein load-
ing, all blots were probed with mouse anti-β-ac-
tin monoclonal antibody. Densitometry of protein 
bands on X-ray film was performed by Image J ana-
lysis PC software.
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Statistical analysis 
Values are expressed as means ± SEM, with 
n values representing the number of experiments. 
Statistical significance was evaluated with Stu-
dent’s t test. The SPSS program for Windows 
(SPSS, Chicago, IL, USA) was used for statistical 
analyses. Value of p < 0.05 was considered sig-
nificant.
Results 
Body mass, plasma and serum metabolic 
profile
Initial body mass was comparable in both the 
control and ghrelin groups. Mass gain during the 
5 days of ghrelin treatment was not changed sig-
nificantly. Blood glucose levels did not change in 
the ghrelin group compared with the control group. 
Plasma insulin level was significantly increased in 
ghrelin-treated rats (p < 0.01). Due to hyperinsu-
linemia and a  slight non-significant increase in 
glucose level, HOMA-IR and HOMA-β indices were 
significantly (p < 0.05) higher in the ghrelin group. 
Plasma FFA was significantly (p < 0.01) lower in the 
ghrelin than in the control group (Table I). 
Effects of ghrelin on protein expressions  
of CuZnSOD, MnSOD, CAT, GPx  
and GR in rat liver 
We designed experiments to elucidate the pos-
sible antioxidant properties of ghrelin by measur-
ing protein expression of the major antioxidant 
enzymes such as SOD, CAT, GPx, and GR in the rat 
liver following 5 days of administration of ghrelin. 
Protein expression of cytoplasmic CuZnSOD, 
MnSOD, CAT (Figure 1), GPx and GR (Figure 2) was 
significantly higher (p < 0.05; p < 0.05; p < 0.01, 
p < 0.001, respectively) in ghrelin-treated, com-
pared with control rats. Taken together, those 
results indicate that ghrelin increased protein ex-
pression of antioxidative enzymes in the rat liver. 
Effects of ghrelin on iNOS protein expression 
and protein level of NFκB in the rat liver 
We have previously shown that ghrelin admin-
istration caused an increase in serum NO [20]. 
Because ghrelin stimulates total plasma NO pro-
duction [20], we next examined whether this ef-
fect of ghrelin is due to upregulation of iNOS. In 
contrast to regulation of NO plasma production 
[20], ghrelin significantly (p < 0.001) reduced iNOS 
protein level in the liver by 42% compared with 
controls (Figure 3).
The promoter of the gene for iNOS is the bind-
ing site for many transcription factors including 
NFκB in the 5’region of the gene for iNOS [12, 40]. 
When rats were treated with ghrelin, the levels 
of NFκB subunits p65 (Figure 4 A) and p50 (Fig- 
ure 4 B) were significantly lower by 30% (p65, p < 
0.001) and by 24% (p50, p < 0.05) compared with 
controls, respectively. These data suggest that NFκB 
plays a significant role in ghrelin-regulated antioxi-
dant enzymes and iNOS expression in the rat liver.
Liver ERK1/2 and Akt phosphorylation
Since we have previously shown that stimula-
tion of iNOS involves activation of Akt and ERK1/2 
by phosphorylation in the heart tissue [20], we 
next examined the effect of ghrelin on phosphor-
ylation state of Akt and ERK1/2 (Figure 5). Ghrelin 
significantly increased (p < 0.01) phosphorylation 
of Akt at Ser473 (Figure 5 B) and ERK1/2 at Tyr42 
and Tyr44 (p < 0.05) (Figure 5 A). Thus, the regu-
lation of liver antioxidative enzymes and iNOS 
protein expression by ghrelin requires activation 
of both ERK1/2 and Akt.
Discussion
The results of the present study demonstrate 
that ghrelin enhanced liver protein expression of 
ZnSOD, MnSOD, CAT, GPx and GR. Furthermore, 
ghrelin reduced liver protein expression of both 
iNOS and p65 and p50 subunits of NFκB. In ad-
dition, ghrelin stimulates the activity of Akt and 
ERK1/2 kinase. 
Low doses of ICV ghrelin treatment for 5 days 
did not increase body mass (Table I). These results 
are in agreement with reports by others which 
show that after ghrelin treatment, there were no 
significant increases in body mass gain [41]. Also, 
these results are not in agreement with literature 
data reported by others [31, 42–44]. This inconsis-
tency in the results could be explained by different 
experimental approaches, different ways of treat-
ing animals as well as doses of applied ghrelin. In 
Table I. Body mass and biochemical characteristics of rats in control and ghrelin treated groups. Values are given 
as mean ± SEM; p < 0.05 was considered significant 
Experimental 
groups
Initial body 
weight [g]
Final body 
weight [g]
Liver 
weight [g]
Glucose 
[mmol/l]
Insulin 
[mIU/l]
HOMA-IR HOMA-β FFA [mmol/l]
Control 234 ±8 235 ±11 9.49 ±0.72 8.32 ±0.20 96 ±7 33 ±2 375 ±16 0.77 ±0.05
Ghrelin 215 ±8 226 ±8 8.85 ±0.47 8.56 ±0.06 193 ±18** 69 ±7* 711 ±71* 0.49 ±0.03**
HOMA-IR index of insulin resistance (homeostasis model assessment), HOMA-β-index of insulin secretion, FFA – free fatty acids,  
*p < 0.05; **p < 0.01
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addition, it is possible that the use of different rat 
strains and different species of animals also con-
tributed to the inconsistency in the results. 
Treatment with ghrelin leads to an increase in 
serum insulin concentration, but had no effect on 
serum glucose concentration, which is consistent 
with results obtained by others [31, 44]. It is im-
portant to note that the findings in the literature 
of ghrelin’s effect on insulin secretion are contra-
dictory [45–47]. Lee et al. [48] reported that ghrelin 
treatment leads to stimulation of insulin secretion 
while Kamegai et al. [49] reported no significant 
increase in insulin concentration after ICV ghrelin 
treatment. It was found that intravenous admin-
istration of ghrelin inhibits insulin secretion even 
at increased concentrations of glucose in humans 
[46, 50]. The contradiction in the results concern-
ing the effects of ghrelin on insulin levels can be 
explained by different doses of applied ghrelin 
[51]. In addition, Arvat et al. [52] demonstrated 
that ghrelin leads to the release of GH in rats and 
humans. Injected ICV ghrelin also leads to stimu-
lation of GH release in rats [41], with much lower 
doses of ghrelin having a more significant effect on 
the secretion of this hormone [53]. It is considered 
that the effects of ghrelin on insulin level were 
achieved via a central effect, i.e. its effect on the 
synthesis of GH, given the low dose of ghrelin and 
short half-life time in circulating ghrelin [41, 54].
We used index values of HOMA-IR and HOMA-β 
to determine whether ghrelin induces IR and af-
fects the ability of pancreatic β cells to secrete 
insulin in rats. Both indices show a  significant 
increase in ghrelin-treated compared with control 
Figure 1. Effects of ghrelin on CuZnSOD (A and B), MnSOD (C and D) and CAT (E and F) protein expression in the 
rat liver. The results are expressed as a fold increase of control (CONTROL arbitrarily set at 1). Results are mean ± 
SEM of 4 separate experiments; p < 0.05 was considered significant (***p < 0.001). B, D, and E are representative 
Western blots
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rats, suggesting that there has been development 
of IR and insulin secretion in treated animals. In 
the early stages of IR, in order to achieve the phys-
iological values of glucose, there is a  compen-
satory increase in insulin concentrations, as our 
results demonstrated. However, after a period of 
compensated IR there is impairment in the trans-
port of glucose, although insulin concentrations 
increased with increasing IR. The results of others 
on the effect of ghrelin on IR are controversial [55]. 
Poykko et al. [56] found that low levels of ghrelin 
in the plasma lead to the development of IR, while 
Vestergaard et al. [57] reported that ghrelin stimu-
lates the development of peripheral IR.
We observed that ghrelin treatment leads to 
a significant decrease in FFA concentration (Table I). 
It is possible that the levels of FFA in the serum 
of animals treated with ghrelin are reduced as 
they are transported and stored in the cells due 
to increased levels of circulating insulin. The FFA 
and glucose are transported from the circulation 
into muscle cells and cardiomyocytes after meals 
or when cells have an increased need for them 
[58–60]. 
Our data show increased protein expression of 
liver ZnCuSOD, MnSOD, CAT, GPx and GR by ghrelin. 
The ability of ghrelin to significantly increase liver 
protein expression of antioxidant enzymes has 
Figure 2. Effects of ghrelin on GPx (A and B) and GR (C and D) protein expression in the rat liver. The results are 
expressed as a fold increase of control (CONTROL arbitrarily set at 1). Results are mean ± SEM of 4 separate exper-
iments; p < 0.05 was considered significant (**p < 0.01; ***p < 0.001). B and D are representative Western blots
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Figure 3. Effects of ghrelin on iNOS protein level in the rat liver. The results are expressed as a fold increase of 
control (CONTROL arbitrarily set at 1). Results are mean ± SEM of 4 separate experiments; p < 0.05 was considered 
significant (***p < 0.01). B is a representative Western blot
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Figure 4. Effects of ghrelin on levels of p65 (A and B) and p50 NFκB (C and D) subunits in the rat liver. Results are 
expressed as a fold increase of control (CONTROL arbitrarily set at 1). Results are mean ± SEM of 4 separate exper-
iments; p < 0.05 was considered significant (***p < 0.001). B and D are representative Western blots
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Figure 5. Effects of ghrelin on ERK1/2 (A and B) and Akt (C and D) phosphorylation in the rat liver. The results 
are expressed as a fold increase of control (CONTROL arbitrarily set at 1). Results are mean ± SEM of 4 separate 
experiments; p < 0.05 was considered significant (*p < 0.05; **p < 0.01). B and D are representative Western blots
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not been demonstrated in the rat liver in vivo, and 
its intracellular signal transduction pathways are 
not well understood. Our results confirm previous 
data on the antioxidative properties of ghrelin in 
other tissues [1, 6, 11, 61–63]. Several researchers 
reported the relationship between OxS and the 
expression or function of ghrelin [4–6]. Previous 
studies have reported that ghrelin has an anti-in-
flammatory action on the oxidative injury of di-
verse organs, such as the heart, liver and pancreas 
[5, 8–12]. In vitro studies, using human polymor-
phonuclear cells incubated with ghrelin, showed 
that ghrelin inhibited ROS generation as mea-
sured by chemiluminescence [5, 64]. Iseri et al. [5, 
65] reported that ghrelin possesses antioxidant 
and anti-inflammatory characteristics. Our obser-
vation of ghrelin stimulation of liver antioxidative 
protein expression is consistent with previous ob-
servations obtained from in vitro studies, where 
the authors proposed that ghrelin could protect 
the liver against oxidative damage [1]. 
Our data may indicate that ghrelin’s effect on 
protein expression of antioxidant enzymes is de-
pendent on some other signaling pathways, such 
as the insulin-like growth factor-1 (IGF-1) signaling 
pathway. Also, these findings raise the possibility 
that ghrelin has indirect effects in the regulation 
of liver actions through IGF-1. However, adminis-
tration of ghrelin did increase plasma IGF-1 [66]. 
Similar to our findings in the heart [20], findings 
from this study support the notion that ghrelin and 
IGF-1 may act in parallel signaling pathways, both 
of which are necessary for the regulation of antiox-
idative enzymes, and that there is a cross-talk be-
tween ghrelin and IGF-1, where ghrelin is activated 
first, which further results in the activation and/
or induction of IGF-1. If induction or activation of 
IGF-1 receptors is needed for the action of ghrelin, 
this would explain why ghrelin induces protein and 
gene expression of antioxidative enzymes [20]. 
In this study, ghrelin reduced liver iNOS protein 
expression (Figure 3). In addition, using qRT-PCR 
analysis (data not shown), we measured the ef-
fects of ghrelin on the amount of Nos2 mRNA and 
the relative rate of transcription of the Nos2 gene. 
Our preliminary results indicated that changes in 
Nos2 mRNA level were due to changes in regula-
tion of its transcription. Reduced Nos2 gene ex-
pression by ghrelin is in agreement with the lit-
erature data showing down-regulated expression 
of gastric iNOS by ghrelin [40]. These data extend 
our previous findings in the heart [20] that ghrelin 
regulates iNOS [20]. According to our knowledge 
there is a lack of literature data about in vivo ef-
fects of ghrelin on iNOS in rat liver.
The promoter of the gene for iNOS is the bind-
ing site for many transcription factors including 
NFκB in the 5 ‘region of the gene for iNOS [40, 67]. 
Our results show that the levels of both p50 
and p65 subunits of NFκB were decreased in rat 
liver cytoplasm after treatment with ghrelin. Thus, 
it is possible that ghrelin in vivo suppresses IκB-α 
phosphorylation and degradation, inhibits NFκB 
nuclear translocation, and prevents iNOS gene 
induction [68]. These results suggest that NFκB 
may represent an important regulatory factor in 
ghrelin-induced expression of iNOS in the rat liver. 
Studies in different cell types provide evidence 
that NFκB activation is modulated by oxidative 
stress [69, 70]. Conversely, increased levels of ROS 
are associated with activation of NFκB [70–72]. In 
addition, it has been shown that increasing the 
ROS-inactivation capacity inside the β cell could 
interrupt the cytokine-induced activation of NFκB 
and reduce the subsequent activation of the iNOS 
promoter [70]. 
The signaling pathway of the ERK1/2 cascade of 
molecules triggers phosphorylation of one anoth-
er, ultimately resulting in activation of NFκB and 
regulation of gene transcription. When activated 
by phosphorylation, ERK1/2 can phosphorylate 
many target proteins, including transcription fac-
tors and protein kinases [73]. The role of ERK1/2 
in the induction of iNOS has been demonstrated 
in several systems [67, 74–76]. Induction of iNOS 
is mediated through the stimulation of ERK1/2 by 
NFκB [67, 76]. In addition, it has been shown that 
ghrelin can activate the signaling pathway IRS-1/
MAPK [77]. The role of the ERK1/2 signaling net-
work in ghrelin-induced activation of NFκB and 
iNOS expression was demonstrated by measuring 
the level of phosphorylation of ERK1/2. The results 
indicate that ghrelin leads to increased phosphor-
ylation of ERK1/2 in the liver (Figure 5 A). 
On the other hand, literature data clearly indi-
cate the important role of Akt in the regulation of 
NFκB and iNOS activation [68]. The results of our 
study show that ghrelin can activate Akt in the liv-
er (Figure 5 B). These results support the fact that 
activation of Akt mediates the effects on iNOS 
and NFκB. These results are in agreement with 
the results reported by others [68], showing that 
the effects of ghrelin on LPS-induced up-regula-
tion of IKK-β and iNOS in gastric mucosa involves 
Akt activation [68]. Signaling through the Src/Akt 
pathway is known to occupy a central stage in the 
receptor (GHS-R)-mediated responses to ghrelin 
stimulation [68, 78, 79], and the recent reports 
suggest that the activity of IKK complex may also 
be subject to inhibition through S-nitrosylation of 
a  specific cysteine residue within the activation 
loop of IKK-β by the endogenous NO donors [68, 
80–82]. 
The data presented in this paper indicate 
that regulation of the rat liver oxidative stress 
enzymes and iNOS by ghrelin involves the Akt/
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ERK1/2 pathways because both Akt and ERK1/2 
phosphorylation were increased by ghrelin ad-
ministration. 
The limitations of this experimental work are 
that no pathological insult was given to the an-
imals to increase the reactive oxygen species in 
liver and then prove that ghrelin is indeed a pro-
tective and anti-oxidant peptide under pathophys-
iological conditions. We plan to investigate the ef-
fects of ICV administered ghrelin on antioxidative 
enzymes as well as iNOS in liver from high fat fed 
rats, a model of obesity associated with insulin re-
sistance. This will allow us to investigate the ben-
eficial effects of ghrelin on antioxidative enzymes 
as well as iNOS in pathophysiological conditions, 
such as obesity associated with insulin resistance. 
We believe that the positive effects of ghrelin in 
the high fat model rats will provide a reasonable 
rationale to further investigate the molecular 
mechanisms involved in ghrelin’s effects on oxida-
tive stress in pathophysiological conditions.
In conclusion, administration of ghrelin could 
promote an antioxidative defense system in the 
rat liver by increasing expression of antioxidative 
enzymes and reducing iNOS and NFκB protein lev-
els through activation of Akt and ERK1/2 kinases. 
This finding extends previous reports concerning 
the antioxidative properties of ghrelin in other tis-
sues [1, 5, 6, 63, 65, 68, 83–86]. 
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